Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

897
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
897
Antifungal Agents01:15

Antifungal Agents

132
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to...
132
Accessory Structures of the Skin: Nails01:05

Accessory Structures of the Skin: Nails

3.8K
Nails are one of the important accessory structures of the skin. They are hard, protective structures that cover the dorsal surface of the distal phalanges of fingers and toes. Nails are composed of specialized keratinized cells and serve various functions, including protection, sensation, and manual dexterity.
The main components of a nail include the following.
Nail Plate: The nail plate is the visible portion of the nail that extends beyond the fingertips or toes. It is a hard, translucent...
3.8K
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

97
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
97
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

780
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
780
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

1.1K
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

KCNQ1 rs163184 Variant Modulates Susceptibility to Classic and DPP-4 Inhibitor-Associated Bullous Pemphigoid.

International journal of dermatology·2026
Same author

Response to Zou et al, "Comment on "Clinical features, treatment outcomes, and immunologic profile of immune checkpoint inhibitor-associated bullous pemphigoid: A retrospective multicenter cohort study"".

Journal of the American Academy of Dermatology·2026
Same author

International development of Investigator Global Assessment scores for pemphigus.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026
Same author

Clinical features, treatment outcomes, and immunologic profile of immune checkpoint inhibitor-associated bullous pemphigoid: A retrospective multicenter cohort study.

Journal of the American Academy of Dermatology·2026
Same author

Labial adhesions as a rare mucosal manifestation of bullous lupus erythematosus in a 15-year-old female.

International journal of women's dermatology·2026
Same author

Dermoscopy of Subungual Squamous Cell Carcinoma: A Systematic Review.

Cancers·2026

Related Experiment Video

Updated: May 6, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

38.4K

Biologic agents in nail psoriasis: efficacy data and considerations.

Aikaterini Kyriakou1, Aikaterini Patsatsi, Dimitrios Sotiriadis

  • 1Aristotle University School of Medicine, 2nd Dermatology Department , Thessaloniki , Greece docmouli@gmail.com.

Expert Opinion on Biological Therapy
|October 26, 2013
PubMed
Summary

Four biologic agents show efficacy for nail psoriasis, but varied study methods necessitate standardized outcome measures for clearer conclusions on treatment effectiveness.

More Related Videos

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
02:28

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Published on: March 1, 2024

1.1K

Related Experiment Videos

Last Updated: May 6, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

38.4K
Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
02:28

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Published on: March 1, 2024

1.1K

Area of Science:

  • Dermatology
  • Immunology
  • Rheumatology

Background:

  • Nail psoriasis significantly impacts overall psoriatic disease assessment.
  • Four biologic agents (adalimumab, etanercept, infliximab, ustekinumab) are approved for plaque psoriasis and are being investigated for nail involvement.
  • Current evidence on the efficacy of these biologics for nail psoriasis requires further investigation.

Purpose of the Study:

  • To review and summarize existing evidence on the efficacy of biologic agents in treating nail psoriasis.
  • To consolidate findings from studies investigating biologic treatments for psoriatic nail disease.

Main Methods:

  • Systematic literature search of MEDLINE and CENTRAL databases.
  • Inclusion of studies reporting on biologic agents used in psoriatic patients with nail involvement.
  • Comprehensive presentation and analysis of relevant data.

Main Results:

  • All four investigated biologic agents demonstrated efficacy in treating psoriatic nail disease.
  • Published data exhibit heterogeneity due to variations in scoring indexes and assessment time points.
  • Drug administration schedules also contribute to data variability.

Conclusions:

  • Consensus on core outcome measures is essential for consistent evaluation.
  • Optimization of existing scoring systems is needed.
  • High-quality, valid clinical trials are required to draw more definitive conclusions on biologic efficacy for nail psoriasis.